EUVIMEDEUVIMED entdecken
Crossref

Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques

Catherine Jacob-Dolan iD, David Hope iD, Jinyan Liu iD, Alejandra Waller-Pulido iD, Brookelynne Verrette, Dalia N Cabrera-Barragan iD, Samuel J Nangle iD, Qixin Wang iD, Ross Blanc iD, Jana Fisher, Ninaad Lasrado iD, Liping Wang iD und 10 weitere

Science Translational Medicine · 09.07.2025 · 17 (806)

DOI: 10.1126/scitranslmed.adu7646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 09.07.2025. Verfasst von Catherine Jacob-Dolan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Adenoviridae, Influenza Vaccines, Orthomyxoviridae Infections, mRNA Vaccines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinically approved seasonal influenza vaccines provide only 10 to 60% efficacy, necessitating strategies to improve vaccine performance. Here, we explored strategies for improving influenza vaccine efficacy using gene-based vaccines and mucosal boosting strategies in nonhuman primates. All vaccinated cynomolgus macaques were primed with the clinical quadrivalent inactivated virus (QIV) vaccine. We evaluated a rhesus adenovirus (RhAd52) vector delivered by intramuscular or mucosal routes and an mRNA vaccine encoding the hemagglutinin of A/H1N1/Wisconsin/67/2022 delivered intramuscularly as boosts compared with the QIV vaccine delivered intramuscularly and the quadrivalent live-attenuated influenza virus (LAIV) vaccine delivered intranasally. Boosting with RhAd52 and mRNA vaccines induced more robust humoral and cellular immune responses than the clinically approved vaccines and provided improved protective efficacy against a high-dose homologous challenge with A/H1N1/Wisconsin/67/2022. The RhAd52 vaccine delivered by the intratracheal route elicited robust mucosal antibody and T cell responses and provided optimal protection in the upper and lower respiratory tracts. Both peripheral and mucosal antibody responses, as well as mucosal T cell responses, correlated with protection against viral loads. Altogether, this study defines strategies for improving H1N1 seasonal influenza vaccine efficacy by using gene-based vaccines and by optimizing mucosal immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeInfluenza VaccinesOrthomyxoviridae InfectionsmRNA VaccinesImmunization, SecondaryMucous MembraneAnimalsInfluenza A Virus, H1N1 SubtypeImmunity, MucosalAntibodies, ViralMacaca fascicularisT-LymphocytesVaccine EfficacyImmunity, CellularMacaca mulatta

Substanzen

Influenza VaccinesAntibodies, ViralmRNA Vaccines

Autor:innen und Institutionen

  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
  • Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.
  • Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Bioqual, Rockville, MD 20850, USA.
  • Pfizer Research and Development, Pfizer Inc., Pearl River, NY 10965, USA.

ORCID-Profile: Catherine Jacob-Dolan, David Hope, Jinyan Liu, Alejandra Waller-Pulido, Dalia N Cabrera-Barragan, Samuel J Nangle, Qixin Wang, Ross Blanc, Ninaad Lasrado, Liping Wang, Anthony Cook, Laurent Pessiant, Mark Lewis, Hanne Andersen, Markay Hopps, Ingrid L Scully, Pirada Suphaphiphat Allen, Ryan P McNamara, Dan H Barouch

Förderung

  • NIAID NIH HHS

Zitieren

APA

Jacob-Dolan, C., Hope, D., Liu, J., Waller-Pulido, A., Verrette, B., Cabrera-Barragan, D. N., Nangle, S. J., Wang, Q., Blanc, R., Fisher, J., Lasrado, N., Wang, L., Cook, A., Pessiant, L., Lewis, M., Andersen, H., Hopps, M., Scully, I. L., Allen, P. S., …, & Barouch, D. H. (2025). Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Science Translational Medicine, 17(806). https://doi.org/10.1126/scitranslmed.adu7646

Vancouver

Jacob-Dolan C, Hope D, Liu J, Waller-Pulido A, Verrette B, Cabrera-Barragan DN, et al. Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Science Translational Medicine. 2025;17(806). doi:10.1126/scitranslmed.adu7646

BibTeX
@article{JacobDolan2025,
  author = {Jacob-Dolan, Catherine and Hope, David and Liu, Jinyan and Waller-Pulido, Alejandra and Verrette, Brookelynne and Cabrera-Barragan, Dalia N and Nangle, Samuel J and Wang, Qixin and Blanc, Ross and Fisher, Jana and Lasrado, Ninaad and Wang, Liping and Cook, Anthony and Pessiant, Laurent and Lewis, Mark and Andersen, Hanne and Hopps, Markay and Scully, Ingrid L and Allen, Pirada Suphaphiphat and McNamara, Ryan P and Anderson, Annaliesa S and Barouch, Dan H},
  title = {Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {806},
  doi = {10.1126/scitranslmed.adu7646}
}
Kostenlos starten →